ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
GSK plc

GSK plc (GSK)

40.48
-0.28
(-0.69%)
At close: June 21 4:00PM
40.48
0.00
( 0.00% )
After Hours: 4:24PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
35.504.106.700.005.400.000.00 %00-
36.003.606.500.005.050.000.00 %00-
36.503.105.900.004.500.000.00 %00-
37.002.655.503.464.0750.000.00 %00-
37.502.204.900.003.550.000.00 %00-
38.001.604.106.502.850.000.00 %04-
38.501.153.800.002.4750.000.00 %00-
39.000.702.906.701.800.000.00 %00-
39.500.452.950.001.700.000.00 %00-
40.000.202.251.001.2250.000.00 %030-
40.500.051.350.050.70-0.55-91.67 %333515:35:37
41.000.201.200.050.70-0.15-75.00 %625715:01:40
41.500.100.050.100.0750.000.00 %033-
42.000.080.050.080.0650.000.00 %0410-
42.500.051.000.050.5250.000.00 %093-
43.000.050.050.050.050.000.00 %03,140-
43.500.001.250.000.000.000.00 %00-
44.000.010.050.010.030.000.00 %224,85714:46:30
44.500.001.150.000.000.000.00 %00-
45.000.030.050.030.040.000.00 %04,641-

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
35.500.001.200.000.000.000.00 %00-
36.000.061.000.060.530.000.00 %0125-
36.500.001.200.000.000.000.00 %00-
37.000.111.000.110.5550.000.00 %0113-
37.500.001.200.000.000.000.00 %00-
38.000.050.050.050.050.000.00 %01,418-
38.500.001.000.000.000.000.00 %00-
39.000.070.950.070.510.000.00 %0193-
39.500.070.050.070.060.000.00 %016-
40.000.050.050.050.050.000.00 %5829414:22:34
40.500.050.450.120.250.000.00 %036-
41.000.251.000.700.6250.40133.33 %4162715:06:12
41.500.051.901.100.9750.3037.50 %83911:31:56
42.001.202.001.681.600.4840.00 %82,76815:09:26
42.500.304.201.752.250.000.00 %013-
43.001.203.802.692.500.9352.84 %2063510:45:31
43.501.405.200.003.300.000.00 %00-
44.002.305.102.933.700.000.00 %0119-
44.502.156.000.004.0750.000.00 %00-
45.002.654.905.203.7750.000.00 %04-

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EPOWSunrise New Energy Company Ltd
$ 0.98
(63.52%)
2.15M
NXLNexalin Technologies Inc
$ 2.22
(35.37%)
2.92M
AGFYAgrify Corporation
$ 0.31
(23.02%)
3.88M
WLDSWearable Devices Ltd
$ 0.54
(13.09%)
70.26k
SOBRSOBR Safe Inc
$ 0.1988
(12.57%)
74.48k
OMICSingular Genomics Systems Inc
$ 0.30
(-14.38%)
18.76k
NMHINatures Miracle Holding Inc
$ 0.5297
(-13.76%)
648.34k
WRNTWarrantee Inc
$ 0.291
(-11.82%)
1.92k
AREBAmerican Rebel Holdings Inc
$ 0.6731
(-11.43%)
3.41M
CMNDClearmind Medicine Inc
$ 1.30
(-10.34%)
48.21k
NVDANVIDIA Corporation
$ 127.00
(0.34%)
12.82M
COMMCommScope Holding Company Inc
$ 1.27
(0.00%)
10.82M
AAPLApple Inc
$ 207.74
(0.12%)
10.09M
GOOGAlphabet Inc
$ 180.93
(0.37%)
5.98M
GOOGLAlphabet Inc
$ 179.71
(0.04%)
5.82M

GSK Discussion

View Posts
Monksdream Monksdream 4 months ago
GSK new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
GSK new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
GSK new 52 week high
👍️ 1
1jas 1jas 10 months ago
has anybody here seen that enzolytics pharm announced that they have a cure for hiv/aids yesterday.
πŸ‘οΈ0
MrHankey MrHankey 11 months ago
Does the name Christian Lamarco (www.culperresearch.com) mean anything to you?
If not, you should know that this "activist investor" (aka "short") has requested through FOIA from the FDA for the below information. Prepare for a hit piece and a stock drop.

"Requesting copies of the letter and/or all communications from the FDA to GSK requesting the withdrawal of GSK's Blenrep from the market in the US, as widely reported in November 2022."

https://www.fda.gov/media/170006/download
πŸ‘οΈ0
Magnum7419 Magnum7419 1 year ago
i am in 100@ 34.56 :)
πŸ‘οΈ0
Magnum7419 Magnum7419 1 year ago
GSK #1 pick!!
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
Post hoc analysis shows that biomarker correlates with response to NY-ESO-1 TCR-T cells in patients with synovial sarcoma https://www.nature.com/articles/s41467-022-32491-x
πŸ‘οΈ0
BottomBounce BottomBounce 2 years ago
$GSK Total Debt is $22.11 Billion // $8.00 should be trading
πŸ‘οΈ0
rosemountbomber rosemountbomber 2 years ago
Anyone know how we will calculate our cost basis in Haleon?
πŸ‘οΈ0
ruke ruke 2 years ago
So, why shares aren't realy mooning in pre-market? Isn't that strange?
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition https://www.medpagetoday.com/meetingcoverage/asco/99071
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
Lete-Cel ASCO data https://www.cgtlive.com/view/lete-cel-exhibits-anti-tumor-activity-long-median-pfs-patients-myxoid-round-cell-liposarcoma

πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
The company has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses LYEL's Epi-R https://lyell.com/our-platforms
πŸ‘οΈ0
4MVault 4MVault 3 years ago
GSK Should buy ATOS
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

From it: ''These data provide an initial rationale as to how tumors with histologies resistant to checkpoint blockade can be successfully targeted with adoptive T-cell therapy. Furthermore, these data are the first to demonstrate successful infiltration of solid tumors by SPEAR T cells, which are able to kill tumor cells. Our data also suggest that antigen loss or alterations in the expression of antigen processing proteins are not primary mechanisms of resistance. Moreover, the therapeutic efficacy may be enhanced through use of a high dose fludarabine-containing preparative lymphodepletion regimen, by promoting greater engraftment at the tumor site, and through modulation of TAM.''
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
They have shared some preclinical data https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165ds1.htm
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
Preclinical data from another group: ''Hepatocellular carcinoma (HCC) is responsible for most of primary liver cancer cases and is the sixth most common cancer in the world with a general 5 year survival rate of 18% due to lack of effective therapy. Adoptive T-cell therapy (ACT) with T-cell receptor–engineered T-cell (TCR-T) against HCC-associated antigen a-fetoprotein (AFP), can redirect human T cells to recognize and kill HCC tumor cells.

However, the clinical efficacy of TCR-T therapy is dependent on the proper expansion, in vivo persistence of T cells that is markedly reduced due to exhaustion-associated dysfunction, and activation induced cell death. To improve persistence of TCR-T cells without modifying TCR affinity, we engineered TCR-T cells to overexpress c-Jun, an AP-1 transcription factor associated with T cell development and activation. In this study, we showed that TCR-T cells overexpressing c-Jun have enhanced expansion capacity in culture, improved cytokine production against HepG2 tumor cells without altering their cytotoxic potential.

Interestingly TCR-T cells overexpressing c-Jun showed resistance to activation induced cell death with decreased expression of inhibitory receptors after stimulation with HepG2 tumor cells. Thus, c-Jun overexpression could be a potential therapeutic agent to enhance the anti-tumor efficacy of TCR-T cells against HCC.''

https://virtual.aai.org/aai/2021/virtual-immunology-2021/317351/mohamed.hussein.the.role.of.c-jun.in.enhancing.tcr-t.function.in.treatment.of.html
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
Some more info https://lyell.com/our-platforms

πŸ‘οΈ0
stillness0007 stillness0007 3 years ago
GSK V TEVA question. The panel of judges heard the case on Feb 23rd. Am I right to understand, usually a decision is made 3-4 months after that? Cause some are saying by end of 2022, which makes no sense to me.
πŸ‘οΈ0
testing4covid testing4covid 4 years ago
Achiko AG: The One Ecosystem that Takes a β€˜Swiss Cheese’ Approach to COVID-19

Great article on an upcoming testing technology:

https://sponsored.bloomberg.com/news/sponsors/features/next-tech-stock/the-next-big-thing-in-health-tech/?adv=33197&prx_t=wmcGAAAAAAUk0NA&prx_ro=s&sref=GS2dzBte



πŸ‘οΈ0
whytestocks whytestocks 4 years ago
Breaking News: $GSK Investors Wish They Could Vote These 2 Healthcare CEOs Out

One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management.  But some investors might ...

Read the whole news GSK - Investors Wish They Could Vote These 2 Healthcare CEOs Out
πŸ‘οΈ0
jondoeuk jondoeuk 4 years ago
Decitabine has been shown to induce cancer-testis antigen expression https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139221
πŸ‘οΈ0
jondoeuk jondoeuk 4 years ago
SITC

Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo

Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)
πŸ‘οΈ0
jondoeuk jondoeuk 4 years ago
Going forward, I would like them to transduce half of the CD4+ T-cells with an NY-ESO-1 specific MHC II restricted TCR [1], and the other half to co-express a CD8a. Combining both CD4+ and CD8+ can induce bystander killing of antigen-negative cancer cells [2,3]. Also, some of the CD4+ can show tumoricidal activity by their own means irrespective of MHC II expression [4-7].

Refs:
1 https://www.nejm.org/doi/full/10.1056/nejmoa0800251
2 https://rupress.org/jem/article/207/11/2469/40645/Bystander-killing-of-cancer-requires-the
3 https://www.nature.com/articles/srep14896
4 https://cancerres.aacrjournals.org/content/70/21/8368.long
5 https://rupress.org/jem/article/154/3/952/49262/Eradication-of-disseminated-murine-leukemia-by
6 https://rupress.org/jem/article/207/3/637/40473/Tumor-reactive-CD4-T-cells-develop-cytotoxic
7 https://www.cell.com/immunity/fulltext/S1074-7613(00)80218-6
πŸ‘οΈ0
jondoeuk jondoeuk 4 years ago
Lyell plan to use defined cell populations [1], improve ex vivo expansion [2-4], and a novel co-stim [5].

Refs:
1 https://www.nature.com/articles/leu2015247
2 https://www.sciencedirect.com/science/article/abs/pii/S1535610820302543
3 https://cancerres.aacrjournals.org/content/75/2/296.long
4 https://link.springer.com/article/10.1007%2Fs00262-012-1378-2
5 https://www.nature.com/articles/s41586-019-1805-z
πŸ‘οΈ0
jondoeuk jondoeuk 4 years ago
Hopefully, trials testing these improvements will start early next year https://www.fiercebiotech.com/biotech/gsk-taps-lyell-immunopharma-to-take-cell-therapy-to-next-level
πŸ‘οΈ0
jondoeuk jondoeuk 4 years ago
A new trial testing the NY-ESO-1 TCR-T cell therapy product [1] which either co-expresses a CD8a [2] or dnTGFßRII [2].

Refs:
1 https://clinicaltrials.gov/ct2/show/NCT04526509
2 (Some of the R&D was conducting with ADAP) https://www.adaptimmune.com/our-company/perspectives/detail/1153/jon-silk-talks-about-our-next-generation-research
πŸ‘οΈ0
MustBeTheTruth MustBeTheTruth 4 years ago
Better Development Tools for a New Golden Era of Psychopharmacology

https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/
πŸ‘οΈ0
T695 T695 4 years ago
Calls might sky rocket tomorrow
πŸ‘οΈ0
T695 T695 4 years ago
Calls for next month
πŸ‘οΈ0
BottomBounce BottomBounce 4 years ago
Trump promises Cincinnati rally that US will end AIDS epidemic and find a cure for childhood cancer 'very shortly'

https://www.businessinsider.com/trump-cincinnati-promises-cure-cancer-and-aids-very-shortly-2019-8
πŸ‘οΈ0
BottomBounce BottomBounce 4 years ago
$GSK Democratic-run House approves its $3 trillion relief measure in vote late Friday https://www.marketwatch.com/story/next-coronavirus-aid-package-expected-to-become-reality-in-june-at-the-earliest-as-house-prepares-to-pass-its-bill-on-friday-2020-05-15?mod=mw_more_headlines
πŸ‘οΈ0
BottomBounce BottomBounce 4 years ago
Here's Why Investors Should Follow Sanofi $SNY and GlaxoSmithKline's $GSK New #Coronavirus #COVID19
Collaboration


https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx
πŸ‘οΈ0
BottomBounce BottomBounce 4 years ago
**** BREAKING HIV $GSK <<<< Drug giant GSK today declared a major breakthrough on a new HIV treatment it was trialling in patients that could prevent the spread of the disease. https://www.standard.co.uk/business/drug-giant-gsk-sees-major-breakthrough-on-hiv-treatment-a4442996.html
πŸ‘οΈ0
Nebuchadnezzar Nebuchadnezzar 4 years ago
GSK-especially now in current market turmoil $35 looks XTRA tasty
πŸ‘οΈ0
BottomBounce BottomBounce 5 years ago
Sci-B-Vac data is in December. That's the drug beating $GSK's Engerix-B

The infection prevention rate for $VBIV 91.4% for Sci-B-Vac

The infection prevention rate for $GSK 76.5% for Engerix-B
πŸ‘οΈ0
BottomBounce BottomBounce 5 years ago
$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK -2.8%) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.
πŸ‘οΈ0
BottomBounce BottomBounce 5 years ago
$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK ) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent
πŸ‘οΈ0
BottomBounce BottomBounce 5 years ago
$GSK and $VBIV VBI Vaccines teams up with Glaxo on therapeutic cancer vaccine https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent
πŸ‘οΈ0
Robbinhood101 Robbinhood101 5 years ago
Watch this one go up with Tesaro approval.
πŸ‘οΈ0
I Need Money I Need Money 5 years ago
Certainly a great LONG term hold. ;)
πŸ‘οΈ0
Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 5 years ago
YIKES haha nice up tick with a great divvy.
πŸ‘οΈ0
I Need Money I Need Money 5 years ago
$41.99 now. :)
πŸ‘οΈ0
Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 6 years ago
Yep 39 now with 5% divvy I don't own it now :(!
πŸ‘οΈ0
DewDiligence DewDiligence 6 years ago
GSK, PFE form consumer-health JV: #msg-145552190.
πŸ‘οΈ0
Dhubbard5 Dhubbard5 6 years ago
I agree with your theory completely make total sense.
πŸ‘οΈ0
debunker1 debunker1 6 years ago
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.

πŸ‘οΈ0
Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 6 years ago
Buy anything below 36 not much down side risk.
πŸ‘οΈ0
Trend-Setter Trend-Setter 6 years ago
Copy of Presentation:

https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/ (downloadble)
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock